• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Asensus Surgical Inc.

    8/22/24 9:29:58 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care
    Get the next $ASXC alert in real time by email
    S-8 POS 1 asxc20240820l_s8pos.htm FORM S-8 POS asxc20240820l_s8pos.htm

    As filed with the Securities and Exchange Commission on August 22, 2024

     

    Registration No. 333-272523

    Registration No. 333-258160

    Registration No. 333-249895

    Registration No. 333-239018

    Registration No. 333-231078

    Registration No. 333-225231

    Registration No. 333-219111

    Registration No. 333-211972

    Registration No. 333-203950

    Registration No. 333-197908

    Registration No. 333-193234

    Registration No. 333-191011

    Registration No. 333-190184

    Registration No. 333-161291

     


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-272523

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-258160

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-249895

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-239018

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-231078

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-225231

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-219111

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-211972

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-203950

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-197908

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-193234

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-191011

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-190184

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-161291

     

    UNDER

    THE SECURITIES ACT OF 1933

     

    ASENSUS SURGICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    11-2962080

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Address of principal executive offices and zip code)

     

     

     

     

    Asensus Surgical, Inc. (fka TransEnterix, Inc., fka SafeStich Medical, Inc.) Amended and Restated Incentive Compensation Plan

    Employment Inducement Restrict Stock Unit Award Agreement

    Employment Inducement Performance Restrict Stock Award Agreement

    Employment Inducement Stock Option Agreement

    Restricted Stock Award Agreement, dated as of October 2, 2013

    2006 Incentive Compensation Plan, as amended

    (Full Title of Plan)

     

     

    Shameze Rampertab

    Executive Vice President and Chief Financial Officer

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Mary J. Mullany, Esquire

    Ballard Spahr LLP

    1735 Market Street, 51st Floor

    Philadelphia, PA 19103

    (215) 864-8631

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This post-effective amendment filed by Asensus Surgical, Inc. (the “Company”) deregisters all securities that remain unsold under the following registration statements on Form S-8 (the “Registration Statements”) filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”):

     

     

    ●

    Registration No. 333-272523, registering 22,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”);

     

    ●

    Registration No. 333-258160, registering 22,000,000  shares of Common Stock;

     

    ●

    Registration No. 333-249895, registering 200,000  shares of Common Stock;

     

    ●

    Registration No. 333-239018, registering 6,000,000  shares of Common Stock;

     

    ●

    Registration No. 333-231078, registering 12,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-225231, registering 15,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-219111, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-211972, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-203950, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-197908, registering 200,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-193234, registering 19,700,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-191011, registering 15,680,775  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-190184, registering 3,000,000  shares of Common Stock (not reverse stock split effected); and

     

    ●

    Registration No. 333-161291, registering 2,000,000  shares of Common Stock (not reverse stock split effected).

     

    On August 22, 2024 (the Effective Time”) the Company completed the merger contemplated by the Agreement and Plan of Merger, dated as of June 6, 2024 (the “Merger Agreement”), by and among the Company, KARL STORZ Endoscopy-America, Inc., a California corporation (“Parent”), and Karl Storz California Inc., a California corporation and a wholly owned Subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent (the “Merger”). Upon consummation of the Merger, at the Effective Time, each outstanding share of Common Stock of the Company (other than shares owned by the Company, Parent or Merger Sub (which shares were canceled)) was automatically converted into the right to receive $0.35 in cash, without interest. In connection with the completion of the Merger and related transactions contemplated by the Merger Agreement, the offerings pursuant to the above-referenced Registration Statements have been terminated.

     

    In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities that had been registered for issuance but remain unsold at the termination of the offerings, this post-effective amendment removes from registration any and all securities that were registered under the Registration Statements and remain unsold at the termination of the offerings. Each of the Registration Statements is hereby amended, as appropriate, to reflect the deregistration of such securities.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on the 22nd day of August 2024.

     

      Asensus Surgical, Inc.  
           
      By: /s/         Shameze Rampertab  
      Shameze Rampertab, Executive Vice President and Chief Financial Officer  

     

    Note: No other person is required to sign this Post-Effective Amendment to the Registration Statements on Form S-8 in reliance upon Rule 478 under the Securities Act of 1933.

     

     
    Get the next $ASXC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASXC

    DatePrice TargetRatingAnalyst
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    9/8/2022$1.50Overweight
    Cantor Fitzgerald
    9/8/2022$1.50Buy
    Stifel
    More analyst ratings

    $ASXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Asensus Surgical downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral

      11/16/23 7:11:26 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Asensus Surgical with a new price target

      Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50

      9/8/22 7:20:54 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Asensus Surgical with a new price target

      Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50

      9/8/22 7:19:37 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care